Under assault from newer therapies in the anti-inflammatory market, Johnson & Johnson has focused on expanding Stelara beyond dermatology—and Monday, it took another big step in that direction. The ...

Johnson & Johnson's big-selling Remicade has held most of its ground against biosimilar competition, thanks in part to some aggressive payer contracts that rivals—including Pfizer—have called into ...

Oct 17 (Reuters) - Pfizer Inc said on Monday it will begin shipping its biosimilar version of Johnson & Johnson's blockbuster rheumatoid arthritis drug Remicade in late November at a 15 percent ...

Remicade biologic functions by inhibiting the action of TNF-alpha, a protein involved in inflammation, as it is a tumor necrosis factor (TNF) alpha inhibitor. Biosimilars are FDA-approved versions of ...

Pfizer is suing Johnson & Johnson, alleging that it induced US health insurers to help it block biosimilar competition to its blockbuster Remicade. Pfizer's Inflectra was the first monoclonal antibody ...

Phase 3 data show treatment with REMICADE® (infliximab) resulted in rapid, significant improvement and long-term response in patients with moderate to severe plaque psoriasis. Findings from the ...

The US Food and Drug Administration (FDA) and Centocor this week warned physicians that new hematologic adverse events, some fatal, have been identified in postmarketing surveillance of patients ...

(Reuters) - U.S. Food and Drug Administration staff members on Friday said Celltrion Inc's biosimilar form of Johnson & Johnson's Remicade arthritis drug appeared "highly similar" to the widely used ...

NEW YORK (Reuters) - Crohn's disease patients taking Johnson & Johnson's Remicade either alone or with azathioprine experienced steroid-free remission in significantly greater numbers than those ...